Is Intuitive Surgical, Inc. (ISRG) Undervalued? Valuation & Fair Price
At $398.30, the frameworks are split on Intuitive Surgical, Inc. today — Warren Buffett and Phil Town (Rule #1) rate it Avoid and Benjamin Graham and Peter Lynch rate it Hold. Each model calculates its own fair value and margin of safety; create a free account to see the exact buy price behind every verdict.
Intuitive Surgical, Inc.
ISRGHealthcare · Medical - Devices · NASDAQ
$398.30
P/E 48.1×
Intuitive Surgical, Inc. is a leading medical technology firm dedicated to advancing patient care by developing, producing, and commercializing sophisticated tools. These innovations empower medical professionals to deliver superior, accessible, and less-invasive treatment options to patients both within the United States and across international markets. Its flagship offering, the da Vinci Surgical System, facilitates intricate operations through a minimally disruptive approach. Expanding beyond surgical applications, the company also provides the Ion endoluminal system, designed for diagnostic interventions like minimally invasive lung biopsies. Complementing its primary systems, Intuitive Surgical supplies a comprehensive array of instruments, including stapling tools, energy devices, and essential core components. Furthermore, it offers structured training programs to ensure proficient use of its technology, alongside extensive customer support services encompassing installation, repairs, and ongoing maintenance. The firm also integrates digital capabilities to deliver unified, connected solutions that optimize hospital performance through actionable insights. Established in 1995, Intuitive Surgical maintains its corporate headquarters in Sunnyvale, California.
Investor scorecard
How the four investors rate Intuitive Surgical, Inc.
A split decision across the frameworks
Investor model analysis
Details lockedAt $398.30, 2 of 4 frameworks say Avoid
Intrinsic Value (DCF)
Warren Buffett's valuation model · select an investor above to switch
Intrinsic Value
Locked — upgrade to viewBuy Below
Locked — upgrade to viewStrong Buy
Locked — upgrade to viewMargin of Safety
Locked — upgrade to viewUnlock buy targets with a free account
Get startedCreate a free account to see buy targets, full checklists & risk analysis Get started
Insider & congress activity
Are insiders buying ISRG?
Over recent SEC Form 4 filings, ISRG insiders bought $0 and sold $12.9M of stock across 44 open-market trades. Insiders sell for many reasons, but they buy for one.
| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| Widman FredrikVP Corporate Controller | Sell | 543 | $203K | Sep 15, 2026 |
| Brosius MarkEVP & Chief Mfg and Supply Cha | Sell | 25 | $9K | Sep 11, 2026 |
| Brosius MarkEVP & Chief Mfg and Supply Cha | Sell | 23 | $8K | Sep 10, 2026 |
| Brosius MarkEVP & Chief Mfg and Supply Cha | Sell | 23 | $8K | Sep 9, 2026 |
| Brosius MarkEVP & Chief Mfg and Supply Cha | Sell | 46 | $17K | Sep 8, 2026 |
Members of Congress have also reported 50 trades in ISRG. See the full insider & congress timeline.
Source: SEC Form 4 filings. Open-market buys & sells only. Not investment advice.
See the interactive insider chart & every tradeScenario analysis
Bear, base & bull
Three growth assumptions, three fair values — and where today's price lands
What's working
Key strengths
Identified by Buffett framework analysis
Company financials
5-Year Financials
Income statement highlights — annual, USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $10.1B | $8.4B | $7.1B | $6.2B | $5.7B |
| Rev. Growth | +20.5% | +17.2% | +14.5% | +9.0% | — |
| Net Income | $2.9B | $2.3B | $1.8B | $1.3B | $1.7B |
| Net Margin | 28.4% | 27.8% | 25.2% | 21.3% | 29.9% |
| EPS (Diluted) | $8.00 | $6.54 | $5.12 | $3.72 | $4.79 |
| Free Cash Flow | Locked — upgrade to view | Locked — upgrade to view | Locked — upgrade to view | Locked — upgrade to view | Locked — upgrade to view |
Full analysis included
See the complete picture for ISRG
Exact buy targets, margin of safety, detailed investor checklists, and risk breakdown — all frameworks, all numbers.
Free: 3 analyses/month · Pay per stock: $4.99 · Pro: $19.99/mo
More Healthcare stocks
Educational Use Only · Not Financial Advice
Analysis, scores, valuations, and buy zones are derived from publicly documented investor frameworks (Buffett, Lynch, Benjamin Graham, Phil Town) for learning purposes only. They are not recommendations from licensed financial advisors. Past performance does not guarantee future results. Prices may be delayed up to 15 minutes. Always conduct your own research before making any investment decisions.